369 related articles for article (PubMed ID: 28382534)
1. Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.
Ellingson BM; Chung C; Pope WB; Boxerman JL; Kaufmann TJ
J Neurooncol; 2017 Sep; 134(3):495-504. PubMed ID: 28382534
[TBL] [Abstract][Full Text] [Related]
2. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Neuroimaging Clin N Am; 2021 Feb; 31(1):103-120. PubMed ID: 33220823
[TBL] [Abstract][Full Text] [Related]
3. Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.
Delgado-López PD; Riñones-Mena E; Corrales-García EM
Clin Transl Oncol; 2018 Aug; 20(8):939-953. PubMed ID: 29218626
[TBL] [Abstract][Full Text] [Related]
4. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
[TBL] [Abstract][Full Text] [Related]
5. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
6. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers.
Le Fèvre C; Constans JM; Chambrelant I; Antoni D; Bund C; Leroy-Freschini B; Schott R; Cebula H; Noël G
Crit Rev Oncol Hematol; 2021 Mar; 159():103230. PubMed ID: 33515701
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
8. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
[TBL] [Abstract][Full Text] [Related]
9. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
Ellingson BM; Wen PY; Cloughesy TF
Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
[TBL] [Abstract][Full Text] [Related]
10. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
Shiroishi MS; Boxerman JL; Pope WB
Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321
[TBL] [Abstract][Full Text] [Related]
11. Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.
Young JS; Al-Adli N; Scotford K; Cha S; Berger MS
J Neurosurg; 2023 Sep; 139(3):748-759. PubMed ID: 36790010
[TBL] [Abstract][Full Text] [Related]
12. Shape Features of the Lesion Habitat to Differentiate Brain Tumor Progression from Pseudoprogression on Routine Multiparametric MRI: A Multisite Study.
Ismail M; Hill V; Statsevych V; Huang R; Prasanna P; Correa R; Singh G; Bera K; Beig N; Thawani R; Madabhushi A; Aahluwalia M; Tiwari P
AJNR Am J Neuroradiol; 2018 Dec; 39(12):2187-2193. PubMed ID: 30385468
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
[TBL] [Abstract][Full Text] [Related]
14. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of Recurrent Glioblastoma from Delayed Radiation Necrosis by Using Voxel-based Multiparametric Analysis of MR Imaging Data.
Yoon RG; Kim HS; Koh MJ; Shim WH; Jung SC; Kim SJ; Kim JH
Radiology; 2017 Oct; 285(1):206-213. PubMed ID: 28535120
[TBL] [Abstract][Full Text] [Related]
16. Impact of Resecting Radiation Necrosis and Pseudoprogression on Survival of Patients with Glioblastoma.
Grossman R; Shimony N; Hadelsberg U; Soffer D; Sitt R; Strauss N; Corn BW; Ram Z
World Neurosurg; 2016 May; 89():37-41. PubMed ID: 26805684
[TBL] [Abstract][Full Text] [Related]
17. The value of
Garcia JR; Cozar M; Baquero M; Fernández Barrionuevo JM; Jaramillo A; Rubio J; Maida G; Soler M; Riera E
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):85-90. PubMed ID: 27503425
[TBL] [Abstract][Full Text] [Related]
18. Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.
Brahm CG; den Hollander MW; Enting RH; de Groot JC; Solouki AM; den Dunnen WFA; Heesters MAAM; Wagemakers M; Verheul HMW; de Vries EGE; Pruim J; Walenkamp AME
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2404-2412. PubMed ID: 30032322
[TBL] [Abstract][Full Text] [Related]
19. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review: Part 1 - Molecular, morphological and clinical features.
Le Fèvre C; Lhermitte B; Ahle G; Chambrelant I; Cebula H; Antoni D; Keller A; Schott R; Thiery A; Constans JM; Noël G
Crit Rev Oncol Hematol; 2021 Jan; 157():103188. PubMed ID: 33307200
[TBL] [Abstract][Full Text] [Related]
20. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.
Li Y; Ma Y; Wu Z; Xie R; Zeng F; Cai H; Lui S; Song B; Chen L; Wu M
Front Immunol; 2021; 12():790674. PubMed ID: 34899760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
